“Am I a candidate for magic mushrooms?” A mystery shopper study of Oregon psilocybin service centers

Clicks: 61
ID: 326805
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #4 of 168 articles by views in Health Affairs Scholar

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 168 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction Oregon is the first US state to permit supervised psilocybin services through a nonmedical, wellness-based model. We examined what prospective clients with psychiatric histories encounter when contacting service centers, including how staff communicate about safety, eligibility, and cost. Methods We conducted a mystery shopper study of 26 licensed service centers in Oregon (7/2025-9/2025), 4 of which closed before calls began, leaving 22 in the sample. We reviewed websites and conducted two waves of scripted phone calls portraying adults with depression. Website and call data were combined at the center level, counting an item as disclosed if it appeared online or during a call. Themes from call field notes were contextualized through structured debriefing interviews with service center staff. Results Callers reached 15/22 centers, none of which permitted unsupervised consumption or immediate dosing without psychiatric assessment. Staff asked detailed questions about psychiatric comorbidities, addressing information gaps from websites, and none recommended discontinuing antidepressants. The median cost was $1,900. Debriefing interviews described financial strain, with viability constrained by licensing fees and potential misalignment with cannabis-derived business models. Conclusion Oregon’s regulated model appears more clinically cautious than skeptics anticipated, while facing high costs for clients and service center staff that limit scalability.
Reference Key
openalex_W7204481116 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Danielle R. Adams, Morgan Hartman, Lijun Gong, Suraj Shankar, Ruth Ling, Jacob T. Steinle, Joshua S. Siegel, Ginger E. Nicol, Richard A. Grucza, Jacob T. Borodovsky, Leopoldo J. Cabassa, Kevin Y. Xu
Are you one of these authors? Claim your profile
Journal Health Affairs Scholar
Year 2026
DOI
10.1093/haschl/qxag231
URL
https://academic.oup.com/healthaffairsscholar/advance-article-pdf/doi/10.1093/haschl/qxag231/70813801/qxag231.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.